Wu Zhou Shi

Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.

Researchers are evaluating the combination of nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor EGFR, with induction chemotherapy, chemoradiation, and adjuvant therapy in patients with locoregionally advanced nasopharyngeal carcinoma. This multi-center, randomized controlled trial aims to assess the therapeutic effectiveness and safety of this combined treatment approach in this cancer type. Participants are assigned to one of two groups the experimental group receives induction chemotherapy with nimotuzumab, gemcitabine, and cisplatin followed by intensity-modulated radiotherapy IMRT combined with weekly nimotuzumab and cisplatin, then adjuvant nimotuzumab every three weeks for eight cycles after IMRT. The control group receives induction chemotherapy with gemcitabine and cisplatin, IMRT combined with weekly nimotuzumab and cisplatin, but no adjuvant nimotuzumab. During the study, participants will undergo regular treatment cycles, radiotherapy sessions, and follow-up assessments over five years. Researchers will monitor overall survival, tumor control, disease-free survival, locoregional failure-free survival, distant metastasis-free survival, adverse events, and quality of life using questionnaires. Safety and treatment effects will be closely observed throughout the trial period, which lasts until November 2027.

Researchers are evaluating the addition of PD-1 treatment to chemo-radiotherapy for high-risk patients with nasopharyngeal carcinoma. This study is a multicenter, open-label, randomized clinical trial comparing outcomes between patients receiving combined PD-1 therapy with chemo-radiotherapy and those receiving chemo-radiotherapy alone. The goal is to see if the combined approach can reduce disease progression and improve survival. Participants are randomly assigned to one of two groups. One group receives three cycles of gemcitabine and cisplatin induction chemotherapy followed by concurrent chemo-radiotherapy with camrelizumab given intravenously during radiotherapy and continued for one year after. The other group receives the same chemotherapy and chemo-radiotherapy without camrelizumab. Radiotherapy is delivered using specific dosing schedules across several target volumes. During the study, participants undergo regular assessments including monitoring for disease progression, survival, treatment-related complications, and quality of life using standardized questionnaires. The primary outcome measured is progression-free survival over three years, with secondary outcomes including overall survival, metastasis-free survival, relapse-free survival, and treatment safety. The total study period extends up to three years for follow-up and evaluation.

Researchers are evaluating a new diagnostic kit that detects Epstein-Barr virus EBV C promoter methylation to help diagnose nasopharyngeal carcinoma. This observational study includes participants who have symptoms or conditions that suggest nasopharyngeal carcinoma or need to be differentiated from it. The goal is to assess how well this methylation detection kit works compared to other standard EBV tests and biopsy results. All participants will undergo diagnostic tests including VCA-IgA, EBNA1-IgA, and EBV-DNA assays. Nasopharyngeal swab samples will be analyzed for EBV C promoter methylation using the new detection kit. A confirmatory biopsy will be performed on all patients to establish a definitive diagnosis. The study aims to compare the diagnostic accuracy of the methylation detection kit with existing tests over a period of up to four weeks from enrollment. Participants will be involved in multiple diagnostic tests and a biopsy to confirm their diagnosis. Researchers will evaluate the sensitivity, specificity, and agreement between the methylation detection kit and other EBV-related tests. The study will also analyze the concordance between different test reagents and sequencing methods. Participant involvement lasts up to four weeks from enrollment to final diagnosis, with careful monitoring of test results and biopsy findings.

Acute ischemic stroke is a leading cause of death worldwide, and intravenous thrombolysis with recombinant tissue plasminogen activator rt-PA within 4.5 hours of symptom onset is the most effective treatment currently available. However, some patients experience stroke progression and early reocclusion after thrombolysis, which can worsen neurological outcomes. This trial evaluates whether early antiplatelet therapy with oral aspirin, given soon after thrombolysis, can improve recovery without increasing bleeding risks. The study randomly assigns patients to receive either early oral aspirin within 3 hours of starting intravenous thrombolysis or a placebo, alongside the best medical care based on current guidelines. Aspirin is administered as a 300 mg dose, either chewed or given via nasogastric tube if swallowing is difficult. The trial includes a control group receiving placebo under similar conditions to compare outcomes. This is a Phase 3, multicenter, quadruple-blind, randomized clinical trial. During the study, participants will be closely monitored for neurological status and functional recovery using the modified Rankin scale at 30 and 90 days after stroke, as well as other assessments like NIH Stroke Scale scores within the first week. Researchers will track early neurological changes and safety outcomes such as intracranial hemorrhage. Follow-up will include evaluations at multiple time points up to 90 days post-stroke to determine the effects of early antiplatelet treatment on stroke recovery.

Researchers are evaluating the safety and effectiveness of edaravone dexborneol sublingual tablets for treating cognitive problems after a stroke in adults aged 40 to 80 years. This exploratory Phase II clinical trial is randomized, double-blind, and placebo-controlled, aiming to compare outcomes between patients receiving the study drug and those receiving a placebo. The study focuses on patients who have had an acute ischemic stroke and developed cognitive impairment. Participants will be randomly assigned to receive either edaravone dexborneol sublingual tablets or a placebo twice daily for 24 weeks. Both groups will follow the same treatment schedule over this period. The trial will monitor and compare the safety and effectiveness of the tablet by assessing cognitive function and other health measures. During the study, participants will undergo evaluations including cognitive tests such as the Vascular Dementia Assessment Scale-cognitive subscale, Mini-Mental State Examination, and Montreal Cognitive Assessment at various times up to 24 weeks. Researchers will also track adverse events, treatment discontinuations, and other stroke-related scales. The total follow-up period for safety monitoring extends to 26 weeks, including after treatment completion or early withdrawal.

This research aims to assess whether immunonutrition can reduce oral mucositis compared with standard nutrition in patients with locally advanced nasopharyngeal carcinoma receiving chemoradiotherapy. Oral mucositis is a common and severe side effect in these patients, causing pain, difficulty swallowing, and malnutrition, which can disrupt treatment and worsen quality of life and prognosis. Nutritional interventions like immunonutrition may help improve immune response, reduce inflammation, and enhance treatment tolerance and outcomes. Participants receive induction chemotherapy with gemcitabine and cisplatin followed by concurrent chemoradiotherapy with intensity-modulated radiotherapy and cisplatin. They are randomly assigned to one of two groups one group receives enteral immunonutrition Oral Impact twice daily starting 5 days before radiotherapy until treatment ends, while the other group receives a standard enteral nutrition formula ENSURE three times daily over the same period. During the study, participants are monitored for the incidence, timing, and duration of severe oral mucositis over 7 weeks. Researchers also assess immune status, inflammatory markers, nutritional and physical function, quality of life, and survival rates up to 2 years after randomization. Safety and adverse events are recorded throughout the study. Participants are expected to follow scheduled visits, laboratory tests, and questionnaires.

Researchers are conducting a prospective cohort study in Southern China to explore the links between Epstein-Barr Virus EBV antibody levels and the risk of developing various cancers. The study aims to determine if EBV is associated with cancer types beyond those already known, like lymphomas, nasopharyngeal carcinoma, and stomach cancer, and to understand the overall cancer burden related to EBV in this region. Molecular evidence suggests EBV plays a role in multiple cancers, but comprehensive population data is still needed. Participants are healthy adults from Zhongshan and Wuzhou cities, aged 30 to 69 years. At enrollment, all participants undergo EBV antibody tests, including VCA-IgA and EBNA1-IgA. The study follows them annually for up to 10 years to monitor cancer incidence, vital status, and immigration status. This observational study does not involve treatment but focuses on collecting data and biological samples to analyze cancer risks related to EBV. During the study, participants will be assessed annually through follow-up visits to record new cancer diagnoses and overall health outcomes. Researchers measure cancer incidence as the primary outcome and all-cause mortality as a secondary outcome over a 10-year period. The study tracks participants health status and location changes to ensure accurate long-term monitoring. This long-term observational approach aims to provide valuable insights into EBVs role in cancer development.

Researchers are evaluating treatments for patients with locoregionally advanced nasopharyngeal carcinoma NPC, a type of cancer affecting the nasopharynx. This study aims to compare two treatment approaches during the era of intensity-modulated radiation therapy IMRT, which has improved local control of the disease. It focuses on whether adding induction chemotherapy IC followed by radiotherapy alone can reduce toxic side effects compared to combining IC with concurrent chemoradiotherapy CCRT. Participants will be randomly assigned to one of two groups. One group receives induction chemotherapy with gemcitabine and cisplatin every three weeks for three cycles, followed by IMRT combined with concurrent cisplatin chemotherapy. The other group receives the same induction chemotherapy followed by IMRT alone without concurrent chemotherapy. IMRT is given five days a week for 6 to 7 weeks with specific radiation doses targeted to the tumor and nearby lymph nodes. During the study, participants will undergo regular assessments including scans and laboratory tests to monitor the cancers response and side effects. The main outcome measured is progression-free survival over three years. Other outcomes include overall survival, failure-free survival rates, response rates, and adverse events. The study monitors treatment effects and safety throughout, with follow-up lasting at least three years after treatment.

Chronic subdural hematoma CSDH is a common neurosurgical condition where fluid collects between layers of the brains protective membranes, causing brain compression and neurological problems. This condition can be life-threatening if severe, and current treatments lack a clear standard due to uncertain long-term outcomes. Researchers are conducting a multicenter randomized trial to compare two surgical methods to find the best treatment approach for CSDH. The study compares neuroendoscopy-assisted hematoma drainage to conventional burr-hole drainage. Neuroendoscopy allows surgeons to see and remove the hematoma more thoroughly using a small bone flap and a visualized neuroendoscope, aiming to reduce residual hematoma and recurrence. Burr-hole drainage uses a single hole to irrigate and drain the hematoma. Both procedures involve continuous drainage for up to 48 hours post-surgery or until drainage stops naturally. Participants will be adults aged 18 to 90 with diagnosed CSDH requiring surgery. Researchers will assess recurrence rates, mortality, neurological function scales, quality of life, complications, drainage time, and hospital stay length over three months after surgery. Follow-up visits occur at Day 0, Day 2, Month 1, and Month 3 to monitor outcomes and safety. The total study duration per participant is three months post-operation.